Provided by Tiger Trade Technology Pte. Ltd.

Outlook Therapeutics, Inc.

0.6334
-0.0115-1.78%
Post-market: 0.6306-0.0028-0.44%18:48 EDT
Volume:6.43M
Turnover:4.13M
Market Cap:153.92M
PE:-0.85
High:0.6640
Open:0.6310
Low:0.6276
Close:0.6449
52wk High:2.54
52wk Low:0.1611
Shares:243.00M
Float Shares:196.00M
Volume Ratio:0.60
T/O Rate:3.28%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.7479
EPS(LYR):-1.7940
ROE:-3.65%
ROA:-143.17%
PB:-14.81
PE(LYR):-0.35

Loading ...

Outlook Therapeutics Names Kevin Lundquist CFO, Replacing Lawrence Kenyon

Reuters
·
Aug 28

Outlook Therapeutics - Lawrence Kenyon to Step Down as CFO Effective September 1, 2026

THOMSON REUTERS
·
Aug 28

Outlook Therapeutics Appoints Kevin Lundquist as Chief Financial Officer as it Prepares for U.S. Commercial Launch of Lytenava™

THOMSON REUTERS
·
Aug 28

Outlook Therapeutics Posts CEO Bob Jahr “Why Now” Investor Conference Webcast on Demand

Reuters
·
Aug 27

Outlook Therapeutics Delays Q2 Form 10-Q Filing After Finance Staff Turnover

Reuters
·
Aug 18

Outlook Therapeutics (OTLK) Stock Looks Fully Valued While Book Value Stays Unclear

Simply Wall St.
·
Aug 15

Outlook Therapeutics CFO Lawrence Kenyon Acquires 101,010 Common Shares Valued at $99,999.9

Reuters
·
Aug 15

Outlook Therapeutics Inc Reports Results for the Quarter Ended June 30 - Earnings Summary

Reuters
·
Aug 14

Outlook Therapeutics Q3 Net Loss Narrows Slightly as Costs Drop

Reuters
·
Aug 14

Outlook Therapeutics Q3 EPS USD -0.15

THOMSON REUTERS
·
Aug 14

Outlook Therapeutics Reports Third Quarter Fiscal Year 2026 Financial Results and Provides Business Update Highlighting FDA Approval of Lytenava™

THOMSON REUTERS
·
Aug 14

Press Release: Outlook Therapeutics Reports Third Quarter Fiscal Year 2026 Financial Results and Provides Business Update Highlighting FDA Approval of Lytenava(tm)

Dow Jones
·
Aug 14

S&P 500 Hits New Record High Following PPI Data: Investor Sentiment Improves, Fear Index Remains In ‘Greed’ Zone

Benzinga Earnings
·
Aug 14

Outlook Therapeutics Gears Up For Q3 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts

Benzinga Earnings
·
Aug 14

U.S. Stocks on the MOVE-EnerSys, Netflix, Salesforce

Reuters
·
Aug 14

Top Premarket Decliners

MT Newswires Live
·
Aug 13

Outlook Therapeutics Prices $55 Million Securities Offering; Shares Down Pre-Bell

MT Newswires Live
·
Aug 13

Outlook Therapeutics Announces Pricing of $55.0 Million Public Offering of Common Stock and Warrants

THOMSON REUTERS
·
Aug 13

Outlook Therapeutics - Combined Public Offering Price Per Share and Warrant is $0.99

THOMSON REUTERS
·
Aug 13

Outlook Therapeutics - Terminates May 13, 2026 Prospectus Supplement for ATM Offering Agreement with H.C. Wainwright

Reuters
·
Aug 13